Fujifilm Irvine Scientific Celebrates 50 Years of Providing Cell Culture Media Products and Services

Article

Originally established in the 1970s as a fetal bovine serum supplier, Fujifilm Irvine Scientific continuously proved its strength in the cell culture solutions space.

On May 11, 2021, Fujifilm Irvine Scientific celebrated 50 years of providing cell culture media products and services.

Originally established in the 1970s as a fetal bovine serum supplier, the company continuously proved its strength in the cell culture solutions space by modernizing embryo culture with commercially available media for in vitro fertilization clinics worldwide and by bringing chemically defined media to biotherapeutic manufacturers, Fujifilm Irvine Scientific said in a company press release. Recently, the company introduced products better suited for cell culture-based vaccine production, and advanced cell and gene therapy applications.

“We have reflected on our trailblazing history and many contributions over the last five decades. Our 50th year coincided with unprecedented challenges from the COVID-19 pandemic,” said Yutaka Yamaguchi, CEO and chairman of the board, Fujifilm Irvine Scientific, in the press release. “We are grateful for the dedication and commitment shown by our employees to uphold our standards of delivering the highest quality products and service under these difficult conditions. We are also humbled by the extraordinary efforts of the community we serve in the fight against the virus and honored that our customers trust Fujifilm Irvine Scientific to provide the critical cell culture media needed to manufacture lifesaving therapies and vaccines, and to support medical applications. We are inspired to continue our mission to improve health through innovation, partnership, and service for the next 50 years.”

Source: Fujifilm Irvine Scientific

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content